Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2016-05-26 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-05-26 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a license and assignment agreement with Mayo Foundation. It details the terms of the agreement, payments, responsibilities, and termination conditions. This type of filing is a regulatory announcement of a significant corporate event rather than a full financial report or earnings release. It is not an annual or quarterly report, nor is it a call transcript or proxy statement. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2016-05-25 English
FORM 10-Q
Interim / Quarterly Report Q1 2016
2016-05-16 English
POST EFFECTIVE AMENDMENT NO. 1
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form S-1 filed with the SEC, related to the registration of securities for resale and exercise of warrants. It includes detailed information about the securities being registered, selling stockholders, and terms of the warrants. The document is a regulatory filing related to capital raising and securities registration, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive content about the securities offering. The document fits the category of Capital/Financing Update (CAP) as it pertains to registration and offering of securities and related amendments.
2016-05-12 English
FORM 10K
Annual Report FY 2015
2016-04-14 English
FORM 10-Q AMENDMENT NO. 1
Interim / Quarterly Report Q3 2015
2016-04-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.